Recently, treatment with the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor palbociclib in combination with endocrine therapy (ET) was incorporated in the National Comprehensive Cancer Network treatment guidelines for patients with HR+/HER2− advanced breast cancer (ABC) [5]. Here, ERBB2 is linked to breast carcinoma.